Scholar Rock (NASDAQ:SRRK) Director Michael Gilman Sells 2,544 Shares of Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Michael Gilman sold 2,544 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $53.87, for a total value of $137,045.28. Following the completion of the sale, the director directly owned 59,511 shares of the company’s stock, valued at $3,205,857.57. This trade represents a 4.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scholar Rock Stock Up 0.9%

Shares of NASDAQ:SRRK traded up $0.48 during trading on Monday, reaching $55.36. 1,182,357 shares of the stock were exchanged, compared to its average volume of 1,407,918. Scholar Rock Holding Corporation has a 1-year low of $27.07 and a 1-year high of $56.54. The stock has a fifty day moving average of $48.43 and a two-hundred day moving average of $46.59. The company has a debt-to-equity ratio of 0.71, a current ratio of 8.64 and a quick ratio of 8.64. The firm has a market cap of $6.63 billion, a price-to-earnings ratio of -15.42 and a beta of 0.67.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.01). During the same quarter last year, the company posted ($0.67) EPS. Research analysts anticipate that Scholar Rock Holding Corporation will post -3.23 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Scholar Rock

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. IFP Advisors Inc grew its position in shares of Scholar Rock by 294.1% in the fourth quarter. IFP Advisors Inc now owns 603 shares of the company’s stock valued at $27,000 after purchasing an additional 450 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Scholar Rock during the fourth quarter valued at approximately $30,000. Summit Securities Group LLC purchased a new position in Scholar Rock in the fourth quarter worth $31,000. EverSource Wealth Advisors LLC grew its position in Scholar Rock by 151.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock worth $38,000 after acquiring an additional 525 shares in the last quarter. Finally, Hilton Head Capital Partners LLC bought a new position in Scholar Rock in the fourth quarter valued at $44,000. Institutional investors own 91.08% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on SRRK. Cantor Fitzgerald reissued an “overweight” rating on shares of Scholar Rock in a research note on Thursday, June 18th. Barclays increased their price target on Scholar Rock from $53.00 to $55.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. JPMorgan Chase & Co. increased their price objective on shares of Scholar Rock from $47.00 to $50.00 and gave the company an “overweight” rating in a research note on Monday, March 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Scholar Rock in a report on Tuesday, April 21st. Finally, Canaccord Genuity Group started coverage on Scholar Rock in a research report on Monday, April 20th. They issued a “buy” rating and a $62.00 price objective on the stock. Four analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $56.00.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).